Evidence map›Paper›PMID 31286285›Full record

ArticleThe AAPS journal2019

Characterization and Quantification of an Fc-FGF21 Fusion Protein in Rat Serum Using Immunoaffinity LC-MS.

Fengping Li, Yan Weng, Guodong Zhang, Xiaogang Han, Dongmei Li, Hendrik Neubert

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Fengping LiBioMedicine Design, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts, 01810, USA. fengping.li@pfizer.com.
Yan WengBioMedicine Design, Pfizer Inc., 1 Portland St, Cambridge, Massachusetts, 02139, USA.
Guodong ZhangPharmacokinetics, Dynamics and Metabolism, Pfizer Inc., 280 Shennecossett Road, Groton, Connecticut, 06340, USA.
Xiaogang HanPharmacokinetics, Dynamics and Metabolism, Pfizer Inc., 280 Shennecossett Road, Groton, Connecticut, 06340, USA.
Dongmei LiCardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc., 1 Portland St, Cambridge, Massachusetts, 02139, USA.
Hendrik NeubertBioMedicine Design, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts, 01810, USA.
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fusion of an Fc moiety to a therapeutic protein is widely applied as a half-life extension strategy. However, unlike monoclonal antibodies, Fc-fusion proteins have been shown to be more susceptible to protease-mediated catabolism. The resultant catabolites may still be pharmacologically active and therefore require characterization. We combined intact protein LC-MS and digestion LC-MS/MS methods to both characterize the biotransformation of the fusion protein, Fc-FGF21, and quantify the intact molecule and its major catabolites in rat serum. The digestion LC-MS/MS assay and intact protein LC-MS assay determined that there were four major catabolites formed in vivo: one amino acid (dC1), two amino acids (dC2), or three amino acids (dC3) clipped off from the C-terminus, and a truncated fragment. By 72 h post dosing, only 66% of the intact protein remained. The digestion method was developed with a sensitivity of 20 ng/mL-10 times more sensitive than the intact protein method at 200 ng/mL. While the digestion approach proved more sensitive, the intact LC-MS method was primarily employed for understanding the biotransformation of the Fc-FGF21 fusion protein in the rat in vivo study. Graphical abstract.

Indexed as

Amino Acid SequenceAnimalsChromatography, AffinityChromatography, LiquidFibroblast Growth FactorsHumansImmunoglobulin Fc FragmentsMass SpectrometryRatsTandem Mass Spectrometryfibroblast growth factor 21Fibroblast Growth FactorsImmunoglobulin Fc FragmentsdigestionFc-FGF21immunoaffinityintact proteinLC-MS

Identifiers

PMID31286285
OpenAlexW2957472381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.